Robert A. Hauser, MD, MBA
Dr. Hauser is a Professor of Neurology, Molecular Pharmacology, and Physiology at the University of South Florida Morsani College of Medicine, in Tampa. He serves as Director of the Clinical Signature Interdisciplinary Program in Neuroscience and as Director of the USF Health Byrd Parkinson's Disease and Movement Disorders Center.
Dr. Hauser earned a medical degree from Temple University School of Medicine, in Philadelphia, Pennsylvania, and completed neurology training at the Eastern Virginia Graduate School of Medicine, Norfolk General Hospital. Dr. Hauser completed a fellowship in Movement Disorders at the University of South Florida and became Center Director in 1994.
Dr. Hauser has authored or co-authored more than 200 peer-reviewed publications and has lectured frequently at scientific meetings around the world. He is Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group, and is a member of the steering committee for the NIH sponsored Neuroprotective Exploratory Trials in Parkinson's Disease program (NET-PD).
His primary research interest is in the development of new medical and surgical treatments for Parkinson's Disease, tremor, dystonia, and restless legs syndrome. He provides injectiosn of botulinum toxin for conditions such as cervical dystonia, blepharospasm, hemifacial spasm, limb dystonia and spasticity.
Click here to access Dr. Hauser's programs on ReachMD, a national radio program.
In this interview, Robert A. Hauser, MD, director of the University of South Florida Byrd Parkinson's Disease and Movement Disorders Center reviews current information on Rytary (IPX066), a new, investigational, extended release formulation of carbidopa/levodopa. click here
To read an article on Rytary: click here
Largest patient enrolled clinicial study article featuring Dr. Robert Hauser: click here